{"id":"W2590341501","doi":"10.1002/ijc.30637","title":"Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, Canada","year":2017,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Public Health Ontario; University of Toronto; Institute for Clinical Evaluative Sciences; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"Canadian Centre for Applied Research in Cancer Control; Eli Lilly and Company; Amgen","keywords":"Medicine; Irinotecan; Cetuximab; Panitumumab; Internal medicine; Colorectal cancer; Discontinuation; Oncology; Refractory (planetary science); Bevacizumab; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004596479,0.0002658914,0.0007374932,0.000361388,0.001630673,0.0007693288,0.0007999681,0.0004111767,0.001420898],"category_scores_gemma":[0.001766595,0.0002641419,0.0007476749,0.001555827,0.0004504639,0.0002463784,0.0004799762,0.0005332588,0.0001054698],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.03255906,"about_ca_system_score_gemma":0.04018754,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9757234,"about_ca_topic_score_gemma":0.991062,"domain_scores_codex":[0.9994408,0.00006149945,0.00004391833,0.00007141107,0.0001402794,0.0002420177],"domain_scores_gemma":[0.9986694,0.0001090376,0.0004245704,0.00002293557,0.0002024101,0.000571706],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.004298708,0.0002912717,0.9736322,0.0003170108,0.0003350985,0.0005440384,0.0005867473,0.000804404,0.0007235988,0.0001876113,0.004269016,0.0140103],"study_design_scores_gemma":[0.0007740901,0.0008902197,0.9901935,0.0001337293,0.0003950957,0.0002981466,0.0008294868,0.002183265,0.0001341134,0.00008878118,0.00404282,0.00003672037],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925635,0.002690509,0.0000556136,0.001038539,0.00004256835,0.0001111386,0.001528133,0.000007980716,0.001961957],"genre_scores_gemma":[0.9965518,0.001147697,0.0001278541,0.0004186162,0.00003600484,0.00003105948,0.0008620957,0.000003271835,0.0008215743],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03255906,"threshold_uncertainty_score":0.2362336,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02082982951251147,"score_gpt":0.313044915800785,"score_spread":0.2922150862882735,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}